Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent NaV1.7 inhibitors
NaV1.7 is a particularly compelling target for the treatment of pain. Herein, we report the discovery and evaluation of a series of piperazine amides that exhibit state-dependent inhibition of NaV1.7. After demonstrating significant pharmacodynamic activity with early lead compound 14 in a NaV1.7-de...
Gespeichert in:
| Veröffentlicht in: | MedChemComm 2017-04, Vol.8 (4), p.744-754 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 754 |
|---|---|
| container_issue | 4 |
| container_start_page | 744 |
| container_title | MedChemComm |
| container_volume | 8 |
| creator | Sparling, Brian A Yi, S Able, J Bregman, H DiMauro, Erin F Foti, R S Gao, H Guzman-Perez, A Huang, H Jarosh, M Kornecook, T Ligutti, J Milgram, B C Moyer, B D Youngblood, B Yu, V L Weiss, M M |
| description | NaV1.7 is a particularly compelling target for the treatment of pain. Herein, we report the discovery and evaluation of a series of piperazine amides that exhibit state-dependent inhibition of NaV1.7. After demonstrating significant pharmacodynamic activity with early lead compound 14 in a NaV1.7-dependent behavioural mouse model, we systematically established SAR trends throughout each sector of the scaffold. The information gleaned from this modular analysis was then applied additively to quickly access analogues that encompass an optimal balance of properties, including NaV1.7 potency, selectivity over NaV1.5, aqueous solubility, and microsomal stability. |
| doi_str_mv | 10.1039/c6md00578k |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6072352</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1897388842</sourcerecordid><originalsourceid>FETCH-LOGICAL-p227k-445d0a674830f7586095ff921e5e792f21712d9eeabc60e8e32938e55acd16e23</originalsourceid><addsrcrecordid>eNpVkE1LAzEYhIMottRe_AU5enBrPjab5CJI_YSiF_W6vN28a2N3N-smLdRfb0URnMsMDDwMQ8gpZzPOpL2oitYxprRZH5CxYDnLhOL88C8zOSLTGN_ZXlIYY_NjMpKMM6OtHBN_7WMVtjjsKHSOrnzKUsgaBEdxC80Gkg8dDTXtfY8DfPoOKbTeYaQQacQGq-S3eE5jgoSZwx47h12ij_DKZ5r6buWXPoUhnpCjGpqI01-fkJfbm-f5fbZ4unuYXy2yXgi9zvJcOQaFzo1ktVamYFbVtRUcFWorasE1F84iwrIqGBqUwkqDSkHleIFCTsjlD7ffLFt01X7MAE3ZD76FYVcG8OX_pvOr8i1sy4JpIdU34OwXMISPDcZUtvuPsGmgw7CJJTdWS2NMLuQX_K50lw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1897388842</pqid></control><display><type>article</type><title>Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent NaV1.7 inhibitors</title><source>Royal Society Of Chemistry Journals 2008-</source><source>PubMed Central</source><creator>Sparling, Brian A ; Yi, S ; Able, J ; Bregman, H ; DiMauro, Erin F ; Foti, R S ; Gao, H ; Guzman-Perez, A ; Huang, H ; Jarosh, M ; Kornecook, T ; Ligutti, J ; Milgram, B C ; Moyer, B D ; Youngblood, B ; Yu, V L ; Weiss, M M</creator><creatorcontrib>Sparling, Brian A ; Yi, S ; Able, J ; Bregman, H ; DiMauro, Erin F ; Foti, R S ; Gao, H ; Guzman-Perez, A ; Huang, H ; Jarosh, M ; Kornecook, T ; Ligutti, J ; Milgram, B C ; Moyer, B D ; Youngblood, B ; Yu, V L ; Weiss, M M</creatorcontrib><description>NaV1.7 is a particularly compelling target for the treatment of pain. Herein, we report the discovery and evaluation of a series of piperazine amides that exhibit state-dependent inhibition of NaV1.7. After demonstrating significant pharmacodynamic activity with early lead compound 14 in a NaV1.7-dependent behavioural mouse model, we systematically established SAR trends throughout each sector of the scaffold. The information gleaned from this modular analysis was then applied additively to quickly access analogues that encompass an optimal balance of properties, including NaV1.7 potency, selectivity over NaV1.5, aqueous solubility, and microsomal stability.</description><identifier>ISSN: 2040-2503</identifier><identifier>EISSN: 2040-2511</identifier><identifier>DOI: 10.1039/c6md00578k</identifier><identifier>PMID: 30108793</identifier><language>eng</language><publisher>Royal Society of Chemistry</publisher><subject>Chemistry</subject><ispartof>MedChemComm, 2017-04, Vol.8 (4), p.744-754</ispartof><rights>This journal is © The Royal Society of Chemistry 2017 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072352/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072352/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,725,778,782,883,27907,27908,53774,53776</link.rule.ids></links><search><creatorcontrib>Sparling, Brian A</creatorcontrib><creatorcontrib>Yi, S</creatorcontrib><creatorcontrib>Able, J</creatorcontrib><creatorcontrib>Bregman, H</creatorcontrib><creatorcontrib>DiMauro, Erin F</creatorcontrib><creatorcontrib>Foti, R S</creatorcontrib><creatorcontrib>Gao, H</creatorcontrib><creatorcontrib>Guzman-Perez, A</creatorcontrib><creatorcontrib>Huang, H</creatorcontrib><creatorcontrib>Jarosh, M</creatorcontrib><creatorcontrib>Kornecook, T</creatorcontrib><creatorcontrib>Ligutti, J</creatorcontrib><creatorcontrib>Milgram, B C</creatorcontrib><creatorcontrib>Moyer, B D</creatorcontrib><creatorcontrib>Youngblood, B</creatorcontrib><creatorcontrib>Yu, V L</creatorcontrib><creatorcontrib>Weiss, M M</creatorcontrib><title>Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent NaV1.7 inhibitors</title><title>MedChemComm</title><description>NaV1.7 is a particularly compelling target for the treatment of pain. Herein, we report the discovery and evaluation of a series of piperazine amides that exhibit state-dependent inhibition of NaV1.7. After demonstrating significant pharmacodynamic activity with early lead compound 14 in a NaV1.7-dependent behavioural mouse model, we systematically established SAR trends throughout each sector of the scaffold. The information gleaned from this modular analysis was then applied additively to quickly access analogues that encompass an optimal balance of properties, including NaV1.7 potency, selectivity over NaV1.5, aqueous solubility, and microsomal stability.</description><subject>Chemistry</subject><issn>2040-2503</issn><issn>2040-2511</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNpVkE1LAzEYhIMottRe_AU5enBrPjab5CJI_YSiF_W6vN28a2N3N-smLdRfb0URnMsMDDwMQ8gpZzPOpL2oitYxprRZH5CxYDnLhOL88C8zOSLTGN_ZXlIYY_NjMpKMM6OtHBN_7WMVtjjsKHSOrnzKUsgaBEdxC80Gkg8dDTXtfY8DfPoOKbTeYaQQacQGq-S3eE5jgoSZwx47h12ij_DKZ5r6buWXPoUhnpCjGpqI01-fkJfbm-f5fbZ4unuYXy2yXgi9zvJcOQaFzo1ktVamYFbVtRUcFWorasE1F84iwrIqGBqUwkqDSkHleIFCTsjlD7ffLFt01X7MAE3ZD76FYVcG8OX_pvOr8i1sy4JpIdU34OwXMISPDcZUtvuPsGmgw7CJJTdWS2NMLuQX_K50lw</recordid><startdate>20170401</startdate><enddate>20170401</enddate><creator>Sparling, Brian A</creator><creator>Yi, S</creator><creator>Able, J</creator><creator>Bregman, H</creator><creator>DiMauro, Erin F</creator><creator>Foti, R S</creator><creator>Gao, H</creator><creator>Guzman-Perez, A</creator><creator>Huang, H</creator><creator>Jarosh, M</creator><creator>Kornecook, T</creator><creator>Ligutti, J</creator><creator>Milgram, B C</creator><creator>Moyer, B D</creator><creator>Youngblood, B</creator><creator>Yu, V L</creator><creator>Weiss, M M</creator><general>Royal Society of Chemistry</general><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>5PM</scope></search><sort><creationdate>20170401</creationdate><title>Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent NaV1.7 inhibitors</title><author>Sparling, Brian A ; Yi, S ; Able, J ; Bregman, H ; DiMauro, Erin F ; Foti, R S ; Gao, H ; Guzman-Perez, A ; Huang, H ; Jarosh, M ; Kornecook, T ; Ligutti, J ; Milgram, B C ; Moyer, B D ; Youngblood, B ; Yu, V L ; Weiss, M M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p227k-445d0a674830f7586095ff921e5e792f21712d9eeabc60e8e32938e55acd16e23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sparling, Brian A</creatorcontrib><creatorcontrib>Yi, S</creatorcontrib><creatorcontrib>Able, J</creatorcontrib><creatorcontrib>Bregman, H</creatorcontrib><creatorcontrib>DiMauro, Erin F</creatorcontrib><creatorcontrib>Foti, R S</creatorcontrib><creatorcontrib>Gao, H</creatorcontrib><creatorcontrib>Guzman-Perez, A</creatorcontrib><creatorcontrib>Huang, H</creatorcontrib><creatorcontrib>Jarosh, M</creatorcontrib><creatorcontrib>Kornecook, T</creatorcontrib><creatorcontrib>Ligutti, J</creatorcontrib><creatorcontrib>Milgram, B C</creatorcontrib><creatorcontrib>Moyer, B D</creatorcontrib><creatorcontrib>Youngblood, B</creatorcontrib><creatorcontrib>Yu, V L</creatorcontrib><creatorcontrib>Weiss, M M</creatorcontrib><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>MedChemComm</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sparling, Brian A</au><au>Yi, S</au><au>Able, J</au><au>Bregman, H</au><au>DiMauro, Erin F</au><au>Foti, R S</au><au>Gao, H</au><au>Guzman-Perez, A</au><au>Huang, H</au><au>Jarosh, M</au><au>Kornecook, T</au><au>Ligutti, J</au><au>Milgram, B C</au><au>Moyer, B D</au><au>Youngblood, B</au><au>Yu, V L</au><au>Weiss, M M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent NaV1.7 inhibitors</atitle><jtitle>MedChemComm</jtitle><date>2017-04-01</date><risdate>2017</risdate><volume>8</volume><issue>4</issue><spage>744</spage><epage>754</epage><pages>744-754</pages><issn>2040-2503</issn><eissn>2040-2511</eissn><abstract>NaV1.7 is a particularly compelling target for the treatment of pain. Herein, we report the discovery and evaluation of a series of piperazine amides that exhibit state-dependent inhibition of NaV1.7. After demonstrating significant pharmacodynamic activity with early lead compound 14 in a NaV1.7-dependent behavioural mouse model, we systematically established SAR trends throughout each sector of the scaffold. The information gleaned from this modular analysis was then applied additively to quickly access analogues that encompass an optimal balance of properties, including NaV1.7 potency, selectivity over NaV1.5, aqueous solubility, and microsomal stability.</abstract><pub>Royal Society of Chemistry</pub><pmid>30108793</pmid><doi>10.1039/c6md00578k</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2040-2503 |
| ispartof | MedChemComm, 2017-04, Vol.8 (4), p.744-754 |
| issn | 2040-2503 2040-2511 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6072352 |
| source | Royal Society Of Chemistry Journals 2008-; PubMed Central |
| subjects | Chemistry |
| title | Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent NaV1.7 inhibitors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T21%3A58%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discovery%20and%20hit-to-lead%20evaluation%20of%20piperazine%20amides%20as%20selective,%20state-dependent%20NaV1.7%20inhibitors&rft.jtitle=MedChemComm&rft.au=Sparling,%20Brian%20A&rft.date=2017-04-01&rft.volume=8&rft.issue=4&rft.spage=744&rft.epage=754&rft.pages=744-754&rft.issn=2040-2503&rft.eissn=2040-2511&rft_id=info:doi/10.1039/c6md00578k&rft_dat=%3Cproquest_pubme%3E1897388842%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1897388842&rft_id=info:pmid/30108793&rfr_iscdi=true |